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We have demonstrated that cardiac fibrosis arises from the differentiation of monocyte-
derived fibroblasts. We present here evidence that this process requires sequential Th1
and Th2 induction promoting analogous M1 (classically activated) and M2 (alternatively
activated) macrophage polarity. Our models are: (1) mice subjected to daily repetitive
ischemia and reperfusion (I/R) without infarction and (2) the in vitro transmigration of
human mononuclear leukocytes through human cardiac microvascular endothelium. In
the mouse heart, leukocytes entered after I/R in response to monocyte chemoattractant
protein-1 (MCP-1), which is the major cytokine induced by this protocol. Monocytes within
the heart then differentiated into fibroblasts making collagen while bearing the markers of
M2 macrophages.T cells were seen in these hearts as well as in the human heart with car-
diomyopathy. In the in vitro model, transmigration of the leukocytes was likewise induced
by MCP-1 and some monocytes matured into fibroblasts bearing M2 markers. In this model,
the MCP-1 stimulus induced a transient Th1 and M1 response that developed into a pre-
dominantlyTh2 and M2 response. An increase in theTh2 product IL-13 was present in both
the human and the mouse models, consistent with its known role in fibrosis. In these sim-
plified models, in which there is no cell death to stimulate an anti-inflammatory response,
there is nonetheless a resolution of inflammation enabling a profibrotic environment. This
induces the maturation of monocyte precursors into fibroblasts.
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INTRODUCTION
The immune system uses similar tools whether responding to
infections or sterile tissue injury. The same steps of an inflamma-
tory response followed by resolution and healing take place under
both circumstances (1). For example, the liberation of heat shock
proteins (2), mitochondrial DNA (3), HMGB1 (high-mobility
group box 1) (4, 5), and a host of other internal components
from dead cells [alarmins (6)] can trigger inflammation in the
absence of infection. Others, such as adenosine (7), apoptotic cell
membranes (8, 9), or self DNA (10), can at the same time initi-
ate the anti-inflammatory response that will bring the organism
back to homeostatic balance. Both types of influences may act via
chemokines that attract different subsets of immunocytes or may
skew the subsequent maturation of the cells (11). In contrast to
that schema, this report describes and defines similar responses,
both proinflammatory and anti-inflammatory, in the absence of
cell death and its associated signaling.
Our murine model of intermittent cardiac ischemia and reper-
fusion (I/R) in vivo, despite the absence of cell death, still results in
an immune response. This treatment, which leads to cardiomyopa-
thy, is the daily repetitive brief (15 min) I/R of a coronary artery,
in which the major chemokine induced is monocyte chemoattrac-
tant protein-1 (MCP-1) and histology reveals interstitial fibrosis
but no necrosis (12). We have shown that the fibrosis results from
an influx of CD34+CD45+ monocytes that become fibroblasts
making collagen (13). As in many models of fibrosis, these cells
bear the markers of M2 macrophages while also assuming the
shape and markers of fibroblasts (14). Because this model does
not result in the death of cardiomyocytes, the mediators inducing
the monocyte influx and transition into fibroblasts are limited in
comparison to those accompanying a myocardial infarct, includ-
ing both proinflammatory and anti-inflammatory or profibrotic
influences (12). Neither the influx nor the fibrosis occurs in ani-
mals when MCP-1 is genetically deleted, indicating the necessity
of this chemokine for initiation of the immune response leading
to fibrosis (15, 16).
To simulate these events using human cells in vitro, we designed
a transendothelial migration (TEM) assay using human cardiac
microvascular endothelial cells (HCMEC) growing on a model
basement membrane over an insert with 8µm pores. Human
mononuclear cells are attracted to migrate through the endothe-
lium and the pores in response to MCP-1 below the insert (17).
Some of the transmigrating monocytes become M1 macrophages,
whereas others become M2 macrophages that mature into fibrob-
lasts, and the numbers of the latter vary with different stimuli.
We have used this TEM model to investigate the response of
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monocytes to Fc receptor engagement (17), angiotensin-II (18),
and ROCK-1 knockdown (19), with parallel results to the cor-
responding in vivo mouse models. As with the in vivo models,
MCP-1 is necessary for the migration of the monocytes through
the endothelium (17). Classically, MCP-1 is regarded as a stimulus
for M1 development, but MCP-1 may be accompanied by other
chemokines to which a subset of monocytes capable of maturation
into M2 macrophages may migrate (20). A major inducer of the
M2 phenotype is the Th2 cell product, IL-13 (11), and addition or
production of IL-13 is required for the formation of monocyte-
derived fibroblasts in our in vitro assay (21). This suggests that it
may be pertinent to human disease states.
Since IL-13 has been associated with fibrosis in the aging heart
and in other organs (21–23), we elected to investigate its pres-
ence and kinetics in our cardiomyopathy model as well as in our
in vitro model. Although IL-13 can be made by many kinds of
cells, the source of it in an inflammatory infiltrate is likely to
be predominantly from T cells, and so we verified the presence
of T lymphocytes. Our data suggest that the presence of a Th2
response is integral to the fibrosis in these models of immune
activation, in which there is an initial induction of the Th1 and
M1 responses that then evolve into a Th2/M2 response in the
absence of cell death. The Th2 response is obligate for the for-
mation of myeloid fibroblasts and the development of a fibrotic
cardiomyopathy.
RESULTS
MURINE IN VIVO MODEL
To quantify the number of M2 macrophages and T lympho-
cytes in heart tissue from shams or animals treated with the
I/R protocol, we digested the heart to isolate cells and per-
formed flow cytometry to measure the expression of the markers
CD45 (cells of hematopoietic origin), CD301 (M2 macrophages),
and CD3 (T cells). These markers were combined with fluo-
rescence from calcein, which identifies viable cells. Mechanical
disruption and digestion of the heart tissue as optimized in
our protocol breaks cardiomyocytes apart, so the live cells are
all non-myocytes, representing endothelial cells, smooth mus-
cle cells, fibroblasts, and any hematopoietic cells that may have
entered the heart. In Figure 1, it can be seen that the number of
CD45+CD301+ M2 macrophages increased after I/R, as did the
number that were CD45+CD301+collagen type I+ (and 38± 7%
of the CD45+CD301+ were positive for collagen type I), consis-
tent with our previous histological results that these cells are in
the heart and are making collagen (13, 14). In addition, it can be
seen that there were also T lymphocytes, identified by their CD45
and CD3 markers. Of note, in human heart tissue from cases of
cardiomyopathy, we also found CD45+ cells in a perivascular loca-
tion expressing either a myofibroblast marker (α-smooth muscle
actin) or the T cell marker CD3, as well as CD301+ α-smooth
muscle actin+ cells (Figure 2).
FIGURE 1 | Flow cytometry for the indicated markers on cells
harvested from mouse hearts after 5 days of I/R or from
sham-treated animals. (A) Through (C) are representative histograms
for sham-treated animals. (D) Through (F) are representative histograms
for I/R animals. (G) Through (I) are summary data graphs.
(A,D,G) Represent the percent of all viable cells (calcein positive) that
were positive for both CD45 and CD301; (B,E,H) are the percent of all
cells positive for CD45 that were also positive for both CD301 and
collagen type I; (C,F,I) are the percent of all viable cells that were positive
for both CD45 and CD3 (n=3, *p<0.05).
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MURINE CYTOKINES
In our mouse model, we were interested in the temporal gene
expression of MCP-1 and IL-13. Our results showed high levels
of MCP-1 mRNA early during the I/R response that waned there-
after (Figure 3). The Th2 product, IL-13, showed a later peak,
but was present throughout the 2-week period of I/R. Neither of
these responses took place in mice deficient in MCP-1 expres-
sion (genetic knockout, KO). IL-33, another mediator of interest
because of its ability to induce IL-13, was increased with a sim-
ilar pattern to that of IL-13. Unlike IL-13, IL-33 was induced in
both the wild-type (WT) and the KO mice, and its expression was
maintained at 14 days in the KO but not the WT mice.
We also measured specific cytokines that would characterize the
T cells in the mouse heart as Th1 or Th2 by performing protein
arrays on sham and I/R hearts after 3 days of treatment (Table 1).
FIGURE 2 | Sections of human hearts with cardiomyopathy were
stained with hematoxylin and eosin (H&E) or by immunofluorescence
for the indicated markers. The white bars are 10µm.
The Th2-related IL-13 protein was the most elevated protein in
I/R over sham levels. The Th2 cytokine IL-4, by contrast, was not
as increased, and neither was the major Th1 cytokine, IFN-γ.
HUMAN IN VITRO MODEL
In our human in vitro TEM assay, we stained macrophages for
M1 versus M2 markers after two different times of migration,
Table 1 | Protein array data from hearts of animals subjected to 3 days
of I/R.
Cytokine Fold change from shama Accession number
G-CSF 0.6±0.2 NP_034101.1
GM-CSF 0.9±0.1 NP_034099.2
IFN-γ 1.8±0.4 NP_032363.1
IL-2 0.9±0.1 NP_032392.1
IL-3 1.1±0.2 NP_034686.2
IL-4 1.9±0.6 NP_067258.1
IL-5 1.7±0.3 NP_034688.1
IL-6 1.4±0.3 NP_112445.1
IL-9 0.7±0.1 NP_032399.1
IL-10 1.0±0.2 NP_034678.1
IL-12p40p70 1.1±0.1 NP_032378.1 (p40)
IL-12p70 1.3±0.1 NP_001152896.1 (p35)
IL-13 3.7±0.9 NP_032381.1
IL-17 2.4±0.8 NP_034682.1
MCP-1 1.5±0.2 NP_035463.1
MCP-5 0.8±0.1 NP_035461.2
RANTES 1.1±0.1 NP_038681.2
SCF 1.7±0.2 NP_038626.1
sTNFR1 2.2±0.5 NP_035739.2
TNF 2.0±0.7 NP_038721.1
Thrombopoietin 3.1±0.9 NP_033405.1
VEGF 1.9±0.6 NP_001020421.2
aCardiac protein densities were obtained from three sham and three I/R animals
normalized to the array positive controls. Densities from I/R animals were divided
by the mean densities of the shams and averaged. Only proteins that gave a
positive signal on the array are included.
FIGURE 3 | Gene expression levels for MCP-1, IL-13, and IL-33 in
wild-type (WT) or MCP-1 knockout (KO) after the indicated number
of days of I/R, expressed as the fold increase over sham levels.
(A) the fold increase of MCP-1 in WT and KO animals over sham levels;
(B) the fold increase of IL-13 in WT and KO animals over sham levels;
(C) the fold increase of IL-33 in WT and KO over sham levels (n=3 for
WT and for KO shams; there was no difference between these groups,
so the numbers were combined for the sham levels shown in the
graph; *p<0.05). The graph for IL-13 is reprinted with permission
from (27).
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FIGURE 4 | Human PBMC were allowed to migrate for the indicated
times through human cardiac microvascular endothelium in response to
MCP-1 and thereafter adhered to poly d-lysine coated coverslips. The
cells were stained for the external markers CD86, CD206, and CD301, and
after fixation and permeabilization, for the internal markers NOS2 and
prolylhydroxylase (labeled prolylhyase in the figure). DAPI was used to stain
cell nuclei blue. The insets are cells at either higher magnification (CD301) or
cells with external staining and an internal marker (CD86 plus NOS2 and
CD206 plus prolylhydroxylase) with white arrows extending from the label.
The white arrow within the center panel indicates a CD86 positive cell in the
low magnification field, and the inset at top right shows a cell that is double
positive for CD86 and CD206. White bars represent 20µm.
early (migrating from 0 to 16 h) and late (cells migrating during
the interval of 16–96 h), plus a group with an additional 6 days of
culture post-migration. Macrophages developing from monocytes
that had migrated early had a round morphology with markers of
M1 macrophages, CD86 and NOS2 (nitric oxide synthase 2 or
inducible NOS) (Figure 4). Cells bearing CD86 were 81± 2% of
the total cells counted (out of 1038 counted from three donors).
No cells bearing CD150, CD206, or CD301 were found at the early
time interval. Many macrophages from monocytes that migrated
later were elongated and had an M2 marker, CD206, as well as mak-
ing prolylhydroxylase (the last enzyme in the pathway of collagen
synthesis). Cells positive for CD206 were 64± 5%, for CD86 were
8± 2%, and double positive for CD206 and CD86 were 5± 1% of
the total cells (1019), indicating the possibility of M1 to M2 con-
version. No CD150 or CD301 positive cells were found in this time
frame. With further culture (6 days), some of the elongated cells
became positive for CD301, another marker for M2 macrophages
(24). Cells positive for CD301 were 23± 5% of the total (471). No
CD150+ cells were seen. Cells positive for CD206 were 61± 4, for
CD86 were 3.4± 0.7, and double positive were 1.9± 0.5 out of a
total of 924.
HUMAN CELL IDENTIFICATION
To characterize further the kinetics of macrophage M2 develop-
ment, we performed quantitative PCR on in vitro human trans-
migrated cells from two different time frames (0–16 and 16–96 h).
The cells were expanded with the mitogens phorbol myristate
acetate (PMA) and calcium ionomycin. To relate gene expression
to a negative control (either unmigrated cultured total leukocytes
or freshly isolated uncultured mononuclear cells) would not have
been productive because many genes are not expressed in these
cells. Therefore, we calculated the gene expression as a percent-
age of the theoretical maximum expression from the same donor’s
total unmigrated mononuclear leukocytes cultured with mitogens.
The mitogen-induced signals from the total cells should not be
biased toward one lineage because they contain all of the starting
cell populations. It can be seen in Figure 5 that two transcription
factors involved in M2 development, KLF4 and SOCS1 (25, 26),
were present early but also increased with later transmigration.
Flow cytometry indicated that CD3+ T cells had also transmi-
grated, and their distribution of CD4 and CD8 subsets after 4 days
of migration was similar to that of the original T cells (fresh
CD3+MNLs were 73± 4% CD4+ and 24± 7% CD8+while trans-
migrated CD3+ cells were 69± 3% CD4+ and 22± 6% CD8+,
n= 3). An analysis of their gene expression showed increased lev-
els of IL-13 mRNA with time [Figure 6 and as we have found in
the in vivo model (27)] in conjunction with dramatically decreased
levels of IFN-γ mRNA (Figure 6). These data indicated that the
lymphokine kinetics were compatible with an early Th1 response
(IFN-γ) followed by a Th2 response (IL-13) and downregulation
of Th1 gene expression.
IL-13 can also be upregulated by IL-33, which is a member of
the IL-1 family (28, 29). We measured the gene expression of IL-33
in our human model, and found that it was highly expressed both
early and late during TEM (Figure 6).
DISCUSSION
Under homeostatic regulation, inflammation is followed by its res-
olution (1). In infections, removal of the responsible agent leads to
the quieting of the immune response. In injury, cell death by var-
ious modes leads to active anti-inflammatory signaling. In our
in vivo and in vitro models, in which cell death is avoided, it
is clear that the same transition from proinflammatory to anti-
inflammatory responses can take place, as well as a subsequent
profibrotic environment. In both simplified in vivo and in vitro
models, the initiating factor is MCP-1, considered a proinflam-
matory signal, but the end stage is fibrosis. In the in vivo model,
the shift from inflammation to fibrosis may be mediated at least
partially by IL-13, which is well known for this effect (30, 31).
Indeed, the targets of IL-13, M2 macrophages, were present in the
heart at that time (3 days). Some of these cells were making col-
lagen, indicating that they had already responded to profibrotic
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FIGURE 5 | Human PBMC transmigrated for 0–16 or 16–96 h were
expanded with mitogens (PMA and calcium ionomycin) and
harvested for RNA. The gene expression levels were expressed as a
percentage of mRNA levels in unmigrated mitogen-expanded total
PBMCs (PMA=100%), giving the percent levels of KLF4 (A) or SOCS1
(B) (n= 3 donors in duplicate).
FIGURE 6 | Human PBMC transmigrated for 0–16 or 16–96 h were
expanded with mitogens and harvested for RNA. Their gene expression
levels were expressed as a percentage of mRNA levels in unmigrated
mitogen-expanded total PBMCs for IL-13 (A), IFN-γ (B), and IL-33 (C) (n=3
donors in duplicate, *p<0.05 for the comparison of the indicated group from
the total PBMC level).
mediators. The source of the IL-13 may be the CD3+ T cells that
transmigrated in response to MCP-1, because IL-13 was lacking
in the MCP-1 knockout. We also demonstrate that T cells were
found in the human heart with cardiomyopathy; this indicates
that our in vivo model may be relevant to human disease. Another
stimulus for the upregulation of IL-13 in WT animals may be
increased IL-33, expected to be made by infiltrating immune cells.
However, IL-33 gene expression occurred even in the absence of
MCP-1. IL-33 can be secreted from cells under mechanical strain
(32), and is constitutively expressed in endothelial cells (33), so
these may be sources of IL-33 that are independent of an inflam-
matory infiltrate. In the MCP-1 KO animals, IL-33 gene expression
did not decline at the 14-day time point, indicating the possibility
that MCP-1 could be responsible for the eventual downregulation
of IL-33 mRNA.
As in the murine in vivo model, the presence of MCP-1 in the
human in vitro model induced first a Th1 (IFN-γ) and M1 (CD86,
NOS2) response that within a day shifted to a Th2 (IL-13) and
M2 (CD206, KLF4, and SOCS1) plus fibrotic (prolylhydroxylase)
response without the addition of any further mediators. Therefore,
the proinflammatory response uncomplicated by known external
stimuli for its resolution was down regulated and evolved into a
fibrotic response. A resolution to this conundrum may be found
in further investigation of the action of MCP-1.
The view of MCP-1 as being responsible only for inflamma-
tion has been challenged by findings in other models; effects
were noted either directly on myeloid cells or indirectly via
T cell production of cytokines. Human monocytes in vitro
and in tumor environments can be induced by MCP-1 to
undergo M2 polarization (34). T cells treated with MCP-1
elaborate IL-4 and IL-13 (Th2 cytokines) (35, 36) and MCP-
1-deficient mice cannot mount Th2 responses (37). Some of
the influence of MCP-1 on the promotion of Th2 responses
may be mediated through MCP-1-induced protein-1 (MCPIP1),
a down regulator of inflammatory responses that degrades
cytokine mRNAs and deubiquitinates TNF receptor-associated
factor family proteins (38, 39), thus allowing an unfettered
Th2 response. MCP-1 may induce both inflammation and anti-
inflammation, perhaps at different times or in different envi-
ronments, and the cessation of its proinflammatory effects
may operate through the induction of anti-inflammatory gene
products.
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In previous studies of myocardial infarction injury (with exten-
sive cell death), the presence of two monocyte subsets, one inflam-
matory and the other reparative, was noted in mouse models
(40) and in human patients (41). In myocardial infarction, the
proinflammatory macrophages are thought to be required for ter-
minal digestion of tissue and removal of necrotic debris, which
would not be necessary in our models. Later after infarction,
reparative macrophages (M2) dominate. Thus, there is the gen-
eration of a temporal pattern such that the influx of inflam-
matory macrophages (phenotypically and functionally identical
to M1 macrophages) early after injury is followed by reparative
macrophages (identified as M2) (11, 42). In our models, despite
the absence of cardiac injury sufficient to cause cell death, there
was a reprise of this temporal pattern, including a transient M1
response followed by a robust M2 response, despite there being
nothing to “repair.” In fact, our previous studies demonstrated a
transition to a state of unrestrained fibrosis resulting from dys-
regulation of immune function in M2 macrophages (14, 21). One
cause may be that IL-13 can drive further production of MCP-
1, which may set up a profibrotic feed forward loop (43). Thus
the fibrotic response may represent dysregulation of a potentially
protective immunological evolution (21).
Members of the adaptive immune system recognize foreign
or altered self molecules via their multichain immunoreceptors,
and innate immune cells recognize conserved pathogen-associated
molecules through their pattern recognition receptors. In the
absence of infection or cognate antigen presentation, however,
there can be cytokine-induced cytokine production by both con-
ventional and innate lymphoid cells (44). For example, the IL-1
family member IL-33 (an alarmin) causes antigen-independent IL-
13 production (28, 29). IL-33 gene expression was present in both
our models, although we do not know if this was an ancillary or
primary stimulus for IL-13 production. The lack of IL-13 and pres-
ence of IL-33 in the MCP-1 knockout animals may be interpreted
as the production of IL-33 in resident cells, which thereafter can-
not induce the production of IL-13 from an absent inflammatory
infiltrate. In either case (antigen recognition or cytokine-induced),
we have demonstrated that MCP-1 alone can initiate an immune
response that moves rapidly through a Th1/M1 inflammatory
stage and into a Th2/M2 anti-inflammatory and profibrotic envi-
ronment. Thereafter, the establishment of a chronically fibrotic
state may depend on dysregulation of the immune response, as in
diseases such as systemic sclerosis (45). Although MCP-1 and its
receptor CCR2 historically have been targeted to reduce inflamma-
tion [reviewed in (46)], the possibility that it may initiate chronic
fibrosis without chronic inflammation has not been considered.
Our simplified models may allow an examination of this issue,
as we propose that MCP-1 may initiate both an M1 and an M2
response leading to fibrosis, or promote M1 to M2 conversion.
The data from a murine model with daily episodes of brief
ischemia not inducing infarction and an in vitro model of
mononuclear cell TEM driven by MCP-1 both demonstrate the
presence of a sequential inflammatory reaction occurring without
evidence of tissue injury or infection and leading to intersti-
tial fibrosis. The reaction is initiated by MCP-1-induced TEM of
mononuclear cells (monocytes and T lymphocytes) and does not
occur in the absence of MCP-1. Initially, the mononuclear cells
FIGURE 7 | Schema of theTh1/M1 andTh2/M2 responses after cells
move through blood vessel endothelium. Monocytes and T cells migrate
through endothelium, initially in response to MCP-1, and including a
primitive (CD34+) monocyte. The Th1 product IFN-γ drives the migrated
monocytes toward the M1 phenotype, although this may be less likely for
the CD34+ subset (faded arrow). MCP-1 itself induces migrated activated
macrophages to secrete MCPIP1 (MCP-1-induced protein-1), which limits
the activated M1 phenotype. During that initial Th1/M1 phase, Th2 activities
such as the secretion of IL-13 begin, and become dominant at later time
points. This may be aided by endothelial cell secretion of IL-33. IL-13 may
promote some M1–M2 transition as well as direct monocyte to M2
maturation. The resulting M2 macrophages can become collagen-secreting
myeloid fibroblasts.
are predominantly in an inflammatory phenotype (M1, Th1) and
secrete cytokines and lymphokines appropriate to that phenotype
(Figure 7).
As the reaction progresses, mononuclear cells of an “anti-
inflammatory”phenotype begin to appear and subsequently dom-
inate the cell population. This is followed by the appearance of a
population of fibroblasts expressing collagen while still bearing the
markers of their myeloid origin (CD45) and alternative polariza-
tion (CD206, CD301). The data suggest that the signaling cascade
also contains intrinsic “brake mechanisms” that limit the inten-
sity and duration of the acute inflammatory response. From the
data presented, we suggest potential signaling molecules that may
orchestrate this “braking” response as well as those initiating the
transition from M1 to M2 phenotypes (Figure 7). We also sug-
gest that our previous findings of CD34+CD45+ cells infiltrating
the mouse heart during injuries may provide evidence for a rel-
atively primitive monocyte precursor for either or both the M1
and M2 macrophages, although the finding of collagen in these
cells suggests that they may be destined preferentially for the M2
phenotype (13, 16).
As described above, IL-33 is a powerful inducer of IL-13 and the
Th2 phenotype without requiring an antigen response. Our data
suggest that it also may be an important factor in the initiation of
a Th2 response in an area of inflammation without tissue necrosis.
In addition, MCPIP1 is secreted from activated M1 macrophages
and has been observed to block M1 signaling (47), so this modu-
lator may also aid in the transition from a Th1/M1 to a Th2/M2
response. Our previous and current data suggest that the chronic
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presence of M2 macrophages is associated with some of them
undergoing maturation into secretory myofibroblasts. The mech-
anism and signaling associated with this maturation has not been
well characterized although the phenomenon has been described
in vivo and in vitro (13, 17, 48, 49). When the stimulus continues,
as it does in our in vivo model, even the basic response may change
its nature to that of a chronic pathology (fibrosis) very different
from the initial inflammation. Having thus identified the sequen-
tial immune responses and the initial signals involved, we will
investigate further pathways and additional responses involved in
chronic fibrosis in future studies.
MATERIALS AND METHODS
ANIMALS AND ISCHEMIA REPERFUSION PROTOCOL
Ten to twelve week old B6.129S4-Ccl2tm1Rol/J (MCP-1-KO) and
C57BL/6J WT mice (both from Jackson Laboratory) were sub-
jected to closed chest surgery as previously described (12). Briefly,
1 week after suture implantation, 15-min occlusions of the left
anterior descending artery were performed for the number of indi-
cated days, allowing a 24-h reperfusion period in between. Mice
were euthanized 5 h after the last ischemic episode. All mice were
fed standard mouse chow and water ad libitum. The investigation
conforms to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health. All animals were
treated in accordance with the guidelines of the Baylor College of
Medicine Animal Care and Research Advisory Committee.
HUMAN HEART TISSUE
Tissue pieces from human hearts with cardiomyopathy were
obtained under an Institutional Review Board-approved proto-
col (50). The formalin-fixed tissue was paraffin embedded and
sectioned.
MOUSE CELL IDENTIFICATION
After 5 days of I/R, mice were anesthetized with 2% isoflurane
followed by cervical dislocation. Hearts were isolated and non-
myocytes were isolated by enzymatic digestion using 0.1 mg/ml
Liberase TH Research Grade (Roche Applied Science), as described
previously (13, 18). For flow cytometric analysis, 1–3× 105 freshly
isolated cells were incubated with 0.5µg biotin-conjugated anti-
CD45 antibody (BD Biosciences) followed by PE/Cy-5-conjugated
streptavidin (BD Biosciences), together with either 0.5µg anti-
CD301 (Abcam Inc)+PE-conjugated anti-rat secondary antibody
(Jackson ImmunoResearch), or PE-conjugated anti-CD3ε (Beck-
man Coulter). Fifty nanomolars calceinAM (Invitrogen Molecular
Probes) was added to measure cell viability (only live cells metab-
olize calcein to an intracellular, green-fluorescent permanent cell
dye). A subset of cells were incubated with antibodies against CD45
and CD301 as described above, then fixed and permeabilized (kit
from BD Pharmingen), and incubated over night with 1µg anti-
collagen type I antibody (Rockland), followed by FITC-conjugated
anti-rabbit secondary antibody (Jackson ImmunoResearch). Flu-
orescence intensities were measured on a Beckman Coulter Epics
XL.MCL using EXPO32 software.
HUMAN CELL IDENTIFICATION
Human heart sections were stained with H&E according to stan-
dard procedures (12). Before immunofluorescence staining, tissue
sections were autoclaved in citrate buffer pH 6 for antigen retrieval
and then permeabilized in 1% Triton X-100; after staining, sections
were exposed to 0.3% Sudan Black in 70% alcohol to quench auto-
fluorescence. Tissue sections were stained as described previously
(17, 18) using anti-CD45 (BD Biosciences), -α-SMA (Sigma),
-CD3ε (Beckman Coulter), and -CD301 (Dendritics).
Cells that transmigrated through an endothelial barrier were
allowed to attach to poly d-lysine-coated coverslips (Neuvitro) at
the bottom of the lower well. The cells were fixed and stained
with anti-CD86 (BioLegend), -CD301 (Dendritics), or appro-
priate isotype controls. For the internal antigens, the cells were
also permeabilized (BD Pharmingen) and stained with anti-
prolylhydroxylase (Millipore), -CD206 (Epitomics), or -NOS2
(Abcam Inc). These were followed by affinity-purified F(ab′)2 IgG
specific fluorochrome-conjugated secondary antibodies (Jackson
ImmunoResearch) and the coverslips were mounted with the cell
nucleus stain DAPI. Microscopy was performed on an Olym-
pus AX70 using a QImaging Retiga 2000R camera. Colors were
assigned and merged using ImageJ software (version 1.46r, NIH).
For cytometry, mononuclear leukocytes were stained fresh or
after a 4-day transmigration with anti-CD3 plus either anti-CD4
or -CD8 (all from R&D Systems). Cells were analyzed on a Cell Lab
Quanta SC flow cytometer (Beckman Coulter) using the Quanta
Analysis software.
PROTEIN ARRAY
After 3 days of I/R, hearts were harvested and protein was iso-
lated using Cell Lysis Buffer (RayBiotech) supplemented with Halt
Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific).
Protein (250µg) was loaded onto standard mouse cytokine anti-
body array membranes (cytokine array C1, RayBiotech). Mem-
branes were processed according to the manufacturer’s instruc-
tions, images on film were scanned, and densitometry was assessed
by ImageJ software.
TRANSENDOTHELIAL MIGRATION
As detailed earlier (17, 18), normal blood was obtained from
volunteers under a protocol approved by the Institutional
Review Board of Baylor College of Medicine. Anticoagulated
blood was fractionated by Ficoll-Hypaque gradient centrifugation
(Histopaque-1077; Sigma) to collect mononuclear cells (PBMC).
For a TEM assay, HCMEC (Lonza, passages 4–9) were seeded on
insert membranes with 8µm pores. Human PBMC [25× 104 in
RPMI 1640 with no serum but with ITS-X (Sigma) and antibiotic-
antimycotic (Invitrogen)] were then added to each insert and the
same medium including 650 ng/ml MCP-1 (R&D Systems) for
chemoattraction was added to the well below. PBMC were allowed
to migrate for 16 h, and then the inserts were moved into new
medium-containing wells (without additional MCP-1) for another
80 h (96 h total migration time, but separate from the 0–16 h time
frame for migration). At the end of each migration period, the
migrated cells were expanded in medium plus 5% FBS (HyClone)
plus PMA plus calcium ionomycin (both from Sigma) for 3 days
and then harvested for RNA.
RNA ISOLATION AND TRANSCRIPTIONAL EXPRESSION
Cells were lysed and total RNA was isolated with TRIzol reagent
(Life Technologies) and treated with RNAse-free DNaseI (Qiagen).
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Complimentary DNA was synthesized from 1µg of RNA with
a Verso cDNA synthesis kit (Thermo Scientific) using random
hexamer and oligo-dT primers (3:1). Real-time PCR amplifica-
tion reactions were performed with SsoAdvancedTM SYBR Green
Supermix (Bio-Rad) in triplicate using a CFX96 thermal cycler
(Bio-Rad). Cycling conditions (annealing temperature/time) were
optimized for each primer pair. Gene expression was measured by
the ∆∆CT method and was normalized to HPRT or 18S riboso-
mal RNA levels. Primers were designed using Primer 31, checked
for homologies using BLAST2 and for secondary structures using
the mfold server3. All primer pairs were verified to adhere to the
MIQE guidelines using a temperature gradient and serial dilutions
(51). Primer sequences (all in 5′–3′):
Human:
KLF4: ACTCGCCTTGCTGATTGTCT and CCCCAAAGT-
CAACGAAGAGA
SOCS1: CGAGCATCCGCGTGCACTTT and GCAGCTCGAA-
GAGGCAGTCGAA
IL-13: CAATGGCAGCATGGTATGG and AGAATCCGCTCAG-
CATCC
IFN-γ: TCCCATGGGTTGTGTGTTTA and GGGTCACCTGA-
CACATTCAA
IL-33: ACCCAAATGCTACCACTGGA and TCCACACATGC-
TAAGCACTCTT
1http://frodo.wi.mit.edu/primer3
2http://blast.ncbi.nlm.nih.gov/Blast.cgi
3http://mfold.rna.albany.edu/?q=mfold/DNA-Folding-Form
HPRT-1: GACCAGTCAACAGGGGACAT and CTTGCGAC-
CTTGACCATCTT
Mouse:
IL-13: TCCAATTGCAATGCCATCTA and TGAGTCCACAGCT-
GAGATGC
MCP-1: TCCACAACCACCTCAAGCACTTC and GGCAT-
CACAGTCCGAGTCACAC
IL-33: GGCTGCTTGCTTTCCTTATG and CCGTTACG-
GATATGGTGGTC
18sRNA:ACCGCAGCTAGGAATAATGGA and GCCTCAGTTC-
CGAAAACCA
HPRT-1: GCCCCAAAATGGTTAAGGTT and TTGCGCT-
CATCTTAGGCTTT
STATISTICAL ANALYSIS
All data are expressed as mean± SE. A two-tailed, unpaired Stu-
dent’s t -test or Mann–Whitney test was used to determine a
significant difference between two groups. The Kruskal–Wallis
ANOVA test with Dunn’s post-test was used for three or more
groups. A p-value<0.05 was considered statistically significant.
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